gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

RPEP-018542011Schwartzentruber, Douglas J; Lawson, David H; Richards, Jon M; Conry, Robert M; Miller, Donald M; Treisman, Jonathan; Gailani, Fawaz; Riley, Lee; Conlon, Kevin; Pockaj, Barbara; Kendra, Kari L; White, Richard L; Gonzalez, Rene; Kuzel, Timothy M; Curti, Brendan; Leming, Phillip D; Whitman, Eric D; Balkissoon, Jai; Reintgen, Douglas S; Kaufman, Howard; Marincola, Francesco M; Merino, Maria J; Rosenberg, Steven A; Choyke, Peter; Vena, Don; Hwu, Patrick

evidence

This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.

Read the original research

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

The New England journal of medicine, 364(22), 2119-27

View on PubMed ↗Publisher’s paper ↗

Citation

Schwartzentruber, Douglas J; Lawson, David H; Richards, Jon M; Conry, Robert M; Miller, Donald M; Treisman, Jonathan; Gailani, Fawaz; Riley, Lee; Conlon, Kevin; Pockaj, Barbara; Kendra, Kari L; White, Richard L; Gonzalez, Rene; Kuzel, Timothy M; Curti, Brendan; Leming, Phillip D; Whitman, Eric D; Balkissoon, Jai; Reintgen, Douglas S; Kaufman, Howard; Marincola, Francesco M; Merino, Maria J; Rosenberg, Steven A; Choyke, Peter; Vena, Don; Hwu, Patrick. (2011). gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.. The New England journal of medicine, 364(22), 2119-27. https://doi.org/10.1056/NEJMoa1012863